医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Zai Lab Announces Participation in September Investor Conferences

2024年08月22日 PM08:30
このエントリーをはてなブックマークに追加


 

SHANGHAI & CAMBRIDGE, Mass.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in September 2024:

Morgan Stanley 22nd Annual Global Healthcare Conference
Location: New York, New York

Cantor Fitzgerald Global Healthcare Conference
Fireside Chat: Thursday, September 19, 2024, 8:00 a.m. ET in Track 2
Location: New York, New York

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious diseases, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240822810993/en/

CONTACT

Investor Relations:

Christine Chiou / Lina Zhang

+1 (917) 886-6929 / +86 136 8257 6943

christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com

Media:

Shaun Maccoun / Xiaoyu Chen

+1 (415) 317-7255 / +86 185 0015 5011

shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com

同じカテゴリーの記事 

  • InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China
  • Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
  • 武田薬品工業: 5つの新しいグローバルCSRパートナーシップに3,200万ドル以上を拠出し、93カ国における健康増進を支援
  • Axcelead DDP and Lilly Enter into Research and Collaboration Agreement
  • GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long